Investment analysts at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Trading Up 6.7 %
GLMD opened at $0.42 on Friday. The stock’s 50 day simple moving average is $0.37 and its 200-day simple moving average is $0.38. The stock has a market cap of $2.09 million, a PE ratio of -0.13 and a beta of 0.83. Galmed Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $5.70.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- What is Put Option Volume?
- Roblox: The Bottom Just Fell Out of the Metaverse
- Investing in Commodities: What Are They? How to Invest in Them
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- Investing in Construction Stocks
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
